C5AR1 and cancer: Mice were treated with a selective C5aR1 antagonist (AcF-[OPdChaWR]; PMX53) [35], which has been demonstrated to effectively reduce C5a-mediated inflammatory responses in animal disease models [36,37,38], including murine melanoma [27], cervical [24] and lung [25] cancers.